Humanoid Robot Patent Race: China Leads in Quantity, US Excels in Quality

The global technological competition is taking on a new dimension in the realm of humanoid robot patents. Recent analyses reveal that China holds a commanding lead in the number of humanoid robot technology patents, while the United States demonstrates superiority in the quality and technological strength of individual patents. This dual leadership has the potential to significantly influence the future development of the humanoid robot market and the shaping of international supply chains.

According to an analysis by LexisNexis Intellectual Property Solutions, China accounts for 73% of humanoid robot patents, particularly in morphology, which refers to the physical structure of robots. It also holds 63% of the global patent portfolio strength. Morgan Stanley reports corroborate this, stating that China filed 7,705 humanoid robot patents over the past five years, compared to 1,561 from the US. In terms of overall patent numbers, GreyB data indicates China holds 9,975 patents, nearly four times more than the US (2,574). Over the last decade, China's patent activity in interaction systems doubled, morphology patents increased by 2.5 times, and control and planning architectures patents jumped fivefold.

Conversely, despite lagging in patent volume, the US stands out in terms of quality. The same LexisNexis analysis shows that while US-based inventors account for only 5% of active morphology-related patent families by the end of 2025, they contribute 11% of global portfolio strength, more than double their share by volume. The United States maintains the highest average patent quality across the three key technology areas: interaction systems, morphology, and control and planning systems. Furthermore, six of the top ten most innovative startups in the humanoid robot sector are Chinese, with companies like Fourier, AgiBot, and LimX Dynamics leading the pack. Only Figure AI, Apptronik, and Agility Robotics from the US made it onto the list.

The implications of these developments for markets and the economy could be substantial. The humanoid robot market is projected to generate annual revenues ranging from $38 billion to $200 billion by 2035, with Goldman Sachs forecasting the production of 1.4 million humanoid robots by the same year, highlighting the immense potential of the sector. China's cost advantage in the supply chain is also noteworthy. According to Morgan Stanley, without Chinese participation, the bill of materials for Tesla's Optimus Gen 2 robot could surge from $46,000 to $131,000. This suggests that the US ban on foreign robots and the FCC's decision to block imports of Chinese humanoid robots aim to foster domestic innovation and address national security concerns.

China's rapid ascent in humanoid robotics is directly linked to Beijing's industrial policies and aggressive national R&D investments. More than 30% of innovation in China is attributed to universities and research institutions. In contrast, US patent activity is more fragmented, with greater involvement from established multinational corporations. The transformation of humanoid robots from a lab curiosity to a venture capital obsession, particularly since 2023, has accelerated global interest and investment.

Analysts and market expectations foresee this competition creating a global bifurcation in the coming period. It is suggested that US firms may need to license intellectual property from China due to its extensive patent portfolio. Experts emphasize that the ability to translate R&D results into commercial success, rather than merely focusing on patent counts, is critical. Over the next three years, humanoid robots are expected to be more widely adopted for semi-structured tasks like warehousing and logistics; however, demonstrating return on investment and operational efficiency will remain key factors for widespread adoption.